Prostate cancer is the second leading cause of cancer death among United States men. However, disease aggressiveness is varied, with low-grade disease often being indolent and high-grade cancer accounting for the greatest density of deaths. Outcomes are also disparate among men with high-grade prostate cancer, with upwards of 65% having disease recurrence even after primary treatment. Identification of men at risk for recurrence and elucidation of the molecular processes that drive their disease is paramount, as these men are the most likely to benefit from multimodal therapy. We previously showed that androgen-induced expression profiles in prostate development are reactivated in aggressive prostate cancers. Herein, we report the down-regulation of one such gene, Sparcl1, a secreted protein, acidic and rich in cysteine (SPARC) family matricellular protein, during invasive phases of prostate development and regeneration. We further demonstrate a parallel process in prostate cancer, with decreased expression of SPARCL1 in high-grade/metastatic prostate cancer. Mechanistically, we demonstrate that SPARCL1 loss increases the migratory and invasive properties of prostate cancer cells through Ras homolog gene family, member C (RHOC), a known mediator of metastatic progression. By using models incorporating clinicopathologic parameters to predict prostate cancer recurrence after treatment, we show that SPARCL1 loss is a significant, independent prognostic marker of disease progression. Thus, SPARCL1 is a potent regulator of cell migration/invasion and its loss is independently associated with prostate cancer recurrence.
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Hevin | synaptic cleft 1 | urogenital sinus | extracellular matrix P rostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in United States men. Controversy currently exists over the best treatment strategy for men with high-risk disease (clinical stage ≥T2c, Gleason score 8-10 or prostate-specific antigen > 20 ng/mL) because 56-65% of these men recur after definitive local therapy (1) (2) (3) (4) (5) . This finding highlights the need for a better understanding of the biologic determinants driving disease progression for both prognostic and therapeutic development.
We and others have recently illustrated that pathways essential for prostate organogenesis are reactivated in prostate cancer (6, 7) . During organogenesis, androgens induce epithelialmesenchymal interactions in the urogenital sinus (UGS) and drive its differentiation into a prostate (8) . We examined early prostate organogenesis shortly after initial androgen exposure, when urogenital sinus epithelia (UGE) migrate and invade into the surrounding mesenchyme and determined that the genes defining this developmental stage were similarly regulated in the transition between low-and high-grade prostate cancers (6) . Among these genes, SPARCL1 (SPARC-like 1/Hevin/SC1), a member of the secreted protein, acidic and rich in cysteine (SPARC) family of matricellular proteins, was down-regulated specifically during embryonic periods of androgen-induced epithelial invasion (6) and in aggressive prostate cancers (6, 9) . Sparcl1 has been shown to mitigate adhesion and to inhibit both fibroblast migration and wound healing (10) . The mechanisms through which Sparcl1 regulates cellular adhesion and migration are not well understood; however, Sparcl1 has been shown to bind type I collagen, a component of the extracellular matrix that potentiates tumor cell migration and invasion (11) (12) (13) . Although the C-terminal domain of SPARCL1 is highly homologous to SPARC, an inhibitor of prostate tumorigenesis and progression (14) , the relationship of SPARCL1 itself to prostate cancer aggressiveness has not been well characterized.
Herein, we describe specific roles for SPARCL1 that originate during prostate formation and are reprised in prostate cancer progression. We demonstrate that SPARCL1 restricts epithelial invasion both during androgen-induced prostate development and in prostate cancer. Mechanistically, we demonstrate that SPARCL1 blocks the activation of the Ras homolog gene family, member C (RHOC), thereby inhibiting cellular movement. We consistently find that SPARCL1 is not only down-regulated in localized, highgrade prostate cancer lesions, but is also further repressed in prostate cancer metastases, thus implicating SPARCL1 as a biomarker of lesions with metastatic potential. Consistent with this finding, in multivariate analyses we find that the loss of SPARCL1 expression is significantly prognostic of metastatic recurrence after surgery. Our findings suggest that loss of SPARCL1 leads to an increase in the migratory potential of prostatic epithelial cells, resulting in a more aggressive and invasive phenotype and thereby driving disease recurrence. These data support the potential utility of SPARCL1 as an independent prognostic factor for prostate cancer progression.
Results

Sparcl1 Inhibits Embryonic Epithelial Bud Expansion in the Prostate.
Physiologic prostate growth occurs in an undifferentiated UGS when androgens induce rapid proliferation and invasion of the UGE into the surrounding mesenchyme to form epithelial prostate buds (15, 16) . During this phase of development, we previously noted a marked suppression of Sparcl1 gene expression (6) . Consistent with this finding, we observed a discrete loss of Sparcl1 protein expression in the invasive epithelial buds compared with the UGE core (Fig. 1A) . Following initial epithelial bud elongation, prostate development continues during branching morphogenesis, a stage that begins in utero and is complete by postnatal day 30 (16) . During this phase, we noted a significant rise in Sparcl1 gene expression that inversely correlated with physiologic androgen levels and paralleled the percent completion of branching morphogenesis (Fig. 1B) (17) . When added to undifferentiated prostate rudiments [embryonic day (E)15.5 male UGS] in organ culture, recombinant Sparcl1 inhibited prostate development. Compared with control-treated UGS, Sparcl1-treated UGS exhibited a significant decrease in the number of prostate epithelial buds observed in whole UGS (Fig. 1C) . However, when examined by immunohistochemistry (IHC), we noted that Sparcl1-treated UGS had multiple small buds that were not identifiable in wholemount preparations ( Fig. 1 C, D , and F). Consistent with this finding, bud length was significantly decreased upon exposure to Sparcl1 (Fig. 1E) , suggesting that although bud initiation occurs, bud elongation is abrogated. Despite diminished prostate epithelial bud outgrowth, Sparcl1-treated UGS showed epithelial proliferation comparable to control tissue (Fig. 1 F and G) . Collectively, these observations suggest that the loss of Sparcl1 expression is necessary for epithelial bud migration and elongation into the surrounding mesenchyme during prostate development.
Sparcl1 Expression Is Suppressed During Adult Prostate Regeneration.
Because Sparcl1 expression is specifically suppressed in migrating epithelial cells during prostate development, we evaluated Sparcl1 expression during androgen-mediated regression and regeneration in the adult prostate. In the mature mouse gland, Sparcl1 is expressed predominantly in luminal (CK8 (Fig. S1D) . Following androgen withdrawal (castration), both Sparcl1 gene and protein expression were elevated ( Fig. 2 and Fig. S1C development, Sparcl1 expression was suppressed during androgeninduced prostatic regrowth (Fig. 2) . Taken together, these findings indicate that Sparcl1 expression is repressed during phases of androgen-stimulated prostatic epithelial growth and invasion in both the embryo and the adult. Considering Sparcl1's role in regulating adhesion and migration, our results suggest that Sparcl1 suppresses epithelial expansion and migration in the prostate.
SPARCL1 Does Not Inhibit Proliferation in the Prostate. Sparcl1 markedly inhibited prostate epithelial bud elongation; however, comparable expression of proliferation markers in Sparcl1-treated prostate organ cultures suggests that Sparcl1 does not regulate proliferation in the prostate. Because Sparcl1's role in proliferation is varied, we further defined SPARCL1-mediated regulation of prostatic epithelial cell growth (10, 18, 19) . We examined cellular proliferation and death in SPARCL1-treated prostate cells and demonstrated that SPARCL1 did not restrict the growth of multiple prostate cancer cell lines (Fig. S2A) . SPARCL1 also did not significantly affect cell cycle progression (Fig. S2B ) or cellular proliferation (Fig. S2C) . SPARCL1 also did not affect cell death (Fig. S2D) . Consistent with prostate organ cultures, these data indicate that SPARCL1 does not regulate cellular proliferation or death in the prostate.
SPARCL1 Inhibits Prostate Cell Adhesion, Migration, and Invasion. We hypothesized that loss of Sparcl1 expression permits epithelial migration and invasion in prostate organogenesis and regeneration, and conversely that Sparcl1 expression restricts these functions in the adult gland. To examine this theory, we used a 3D invasion assay in which single-cell epithelial isolates from adult murine prostates can be cultured in Matrigel to form "prostaspheres." This process is dependent on proliferation and 3D migration and invasion into an extracellular matrix. Addition of Sparcl1 to this matrix significantly limited prostasphere number (Fig. 3A) and size ( Fig. 3B ) without affecting differentiation (CK14, CK8, and p63) or proliferation (Ki67) (Fig. S3A) . Augmenting Sparcl1 before or after prostasphere initiation yielded a similar effect (Fig. S3 B and C) . Similar to the mouse, SPARCL1 restricts prostasphere formation in benign adult human primary prostate epithelial cells (Fig. S3D) .
Because prostasphere culture requires attachment to an extracellular matrix, and previous studies have shown that Sparcl1 is antiadhesive (10, 20) , we tested the hypothesis that SPARCL1 may prevent prostate cellular adhesion to various extracellular matrices. SPARCL1 delayed or abrogated adhesion of multiple prostate cancer cell lines and primary benign prostate cells to type I collagen, a key element within the extracellular matrix, and one to which SPARCL1 has been shown to bind (Fig. 4 A and B, Fig. S4 , and Movies S1 and S2.) (11) . Because adhesion is an initiating event leading to a migratory/invasive phenotype, we further examined how SPARCL1 affects cellular migration and extracellular matrix invasion and found that SPARCL1 inhibited prostate cell migration across a membrane (Fig. 4C) . To better elucidate this phenotype, we tested the effects of SPARCL1 on type I collagen-mediated movement. Time-lapse microscopy of prostate cancer cells on a type I collagen matrix containing SPARCL1 or vehicle demonstrated that SPARCL1 not only delayed adhesion to type I collagen, but also inhibited migration following adhesion (Fig. 4D , and Movies S1 and S2). Because invasion can be viewed as migration through a matrix, cells that migrate ineffectively should also show defects in invasion. Accordingly, SPARCL1 also inhibited prostate cancer cell invasion as assayed in type I collagen-based extracellular matrices (Fig. 4E) . Collectively, these data support a role for SPARCL1 in regulating the migratory and invasive potential of prostate cancer cells by inhibiting their adhesive and migratory properties. RHOC has established roles in promoting cancer cell adhesion, migration, invasion, and metastatic progression (21, 22) . Type I collagen engagement of its cognate receptor (α2β1-integrin) has been shown to promote prostate cancer invasion through RHOC (12) . As Sparcl1 has been shown to bind to type I collagen, we hypothesized that SPARCL1 restricts epithelial migration by directly disrupting the function of type I collagen-RHOC-induced migration (11) . Following adhesion to a type I collagen/SPARCL1 matrix, prostate cancer cells exhibited cellular dynamics (Movies S1 and S2), consistent with inhibition of RHOC but not RHOA (23) . To address the possibility that SPARCL1 inhibits type I collagen-induced RHOC activation, we measured RHOC activation in prostate cancer cells following adhesion to one of two different matrices: a type I collagen matrix containing either BSA (control) or SPARCL1. Specific immunoprecipitation (IP) of its active (GTP-bound) form demonstrated that RHOC activation was significantly suppressed when cells were grown on a type I collagen matrix containing SPARCL1 (Fig. 5A ). This effect was specific for RHOC because SPARCL1 did not affect activation of RHOA (Fig. 5A) . SPARCL1 appeared to suppress migration largely by inhibiting RHOC activation, as the effect of SPARCL1 was rescued by overexpressing a constitutively active RHOC mutant (RHOC G14V) (Fig. 5B) . In addition, we found that inhibition of the type I collagen receptor with a neutralizing antibody resulted in RHOC inhibition that was comparable to that mediated by SPARCL1. In contrast, simultaneous exposure to SPARCL1 and a α2β1-integrin-blocking antibody did not further enhance RHOC inhibition, suggesting that SPARCL1 and α2β1-integrin function through the same pathway (Fig. 5C ). Collectively, these data indicate that SPARCL1 inhibits type I collagen-induced RHOC mediated migration.
SPARCL1 Expression Inversely Correlates with Prostate Cancer
Aggressiveness. Because SPARCL1 regulated cell invasion, we postulated that SPARCL1 may correlate with and potentially modulate locally aggressive prostate cancers. To examine this theory, we first evaluated Sparcl1 protein expression in two genetic animal models of prostate cancer. Hi-Myc transgenic mice develop murine prostatic intraepithelial neoplasia (mPIN) and locally invasive adenocarcinoma caused by prostate specific overexpression of c-Myc (24) . In Hi-Myc mice, Sparcl1 expression was decreased in invasive prostate adenocarcinoma (Fig. S5A) . We further examined Sparcl1 expression in both primary and metastatic lesions isolated from transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, a model with high rates of metastasis (25) . Compared with benign adjacent glands and mPIN, Sparcl1 expression was decreased both in invasive prostate adenocarcinoma and in lesions which had metastasized to the liver (Fig. S5 B and  C) . Taken together, these data indicate Sparcl1 loss predates metastasis and therefore may have prognostic value. In human prostate cancer, Gleason grade is the strongest single predictor of prostate cancer lethality (1). Low-grade (sum 6 or less) rarely progress, whereas men with high-grade tumors (sum 8-10) frequently progress to metastasis and death, even after radical treatment (1, 26) . IHC analysis of SPARCL1 expression on tissue microarrays (TMAs) demonstrated a statistically significant inverse correlation between Gleason grade and SPARCL1 expression (Fig.  6 A and B) . Consistent with this finding, analyses of 10 datasets indicated that parallel to protein expression, SPARCL1 gene expression declined continuously as grade increased with the most striking loss seen in metastatic lesions (Fig. 6C and Fig. S6 A-C) (27-36) (Oncomine; www.oncomine.org). In contrast, SPARCL1 gene expression was not significantly lost in benign prostatic hyperplasia or PIN (Fig. S6 D and E) (27, 28, 37) (Oncomine). Interestingly, gene-profiling data from the same cohorts showed that RHOC gene expression did not correlate with prostate cancer grade (Fig. S6 F and G) (27, 28) , suggesting that alterations in RHOC activity as opposed to expression levels, mediate RHOCinduced metastatic progression (38) .
We additionally investigated SPARCL1 expression in other primary cancers and their metastases and also found it decreased in a variety of cancer types, including bladder (39), breast (40) , and lung (41) (Oncomine) (Fig. S6I ) with further supression in metastases compared with primary tumors (Fig. S6J ) (41-47) (Oncomine). These observations suggest that SPARCL1 suppression is a conserved and critical step in cancer progression to metastasis. treatment. Although current models incorporating Gleason grade, pathologic stage, and other clinical parameters predict recurrence (48) , further delineation of risk is needed. We postulated that SPARCL1 loss could add prognostic power to these traditionally used variables. We examined SPARCL1 expression by IHC in a matched nested case-control cohort designed to evaluate prognostic factors for recurrence following prostatectomy (defined as prostate-specific antigen ≥0.2 ng/mL, metastasis, or prostate cancer death) independent of Gleason grade, pathologic stage, age, and other clinical variables [The Johns Hopkins University (JHU) progression array] (32) (Fig. S7A) . We found that loss of SPARCL1 expression in prostate adenocarcinoma was independently associated with a 3.48-fold (95% confidence interval 1.02-11.85; P = 0.046) higher risk of prostate cancer recurrence (Fig. S7) . We validated this finding in an independent cohort using Affymetrix exon microarray analysis in a prospectively-designed study of high-risk men who underwent radical prostatectomy at the Mayo Clinic (Fig. S8A) . We evaluated the prognostic utility of SPARCL1 using three clinical endpoints: biochemical recurrence (BCR), metastatic disease (MET) as defined by a positive bone scan or CR/MRI evidence of metastatic disease, and prostate cancer-specific mortality (PCSM). Kaplan-Meier analyses show loss of SPARCL1 is a powerful single-gene predictor of aggressive prostate cancer (Fig. 6D) . For BCR, loss of SPARCL1 expression was associated with a median time-toprogression of 3.5 y compared with greater than 8 y for high SPARCL1-expressing men. Similarly, for MET-free survival, men with loss of SPARCL1 expression had 5 y MET-free survival of ∼60% vs. ∼80% for men with high SPARCL1 expression. These data suggest that even in a high-risk cohort, where most individuals are expected to experience recurrence at some point after surgery, loss of SPARCL1 expression defines a subgroup where BCR will occur sooner and the risk for developing metastatic disease and prostate cancer death is significantly higher.
Furthermore, multivariable Cox regression analyses of the Mayo Clinic cohort confirmed the JHU observation that loss of SPARCL1 expression is independently prognostic of prostate cancer aggressiveness with significant hazard ratios (HR) for predicting BCR, MET, and PCSM [HR 1.40, P = 0.0045; HR 1.62, P = 0.0007; HR 1.77, P = 0.0028, respectively] (Fig. S8B) . In groups of men stratified by Gleason score (sum 7 and sum ≥8), SPARCL1 suppression significantly identified men at increased risk of developing metastatic disease (Gleason sum 7, HR 1.55, P = 0.03 and Gleason sum ≥8 HR 1.86 P = 0.03) (Fig. 6E) . In fact, in these Gleason subgroups, multivariable Cox regression analyses of SPARCL1 and standard prognostic factors including stage demonstrated that loss of SPARCL1 expression was the only statistically significant predictor of recurrence (Fig. S8C ).
Discussion
Enrichment of embryonic gene-expression signatures has been demonstrated in multiple solid malignancies, substantiating the paradigm of embryonic reawakening in cancer and the utility of embryonic systems to model cancer progression (6, 7, 49) . With this approach, we show that the developmental regulation of Sparcl1 expression is paralleled in prostate cancer. Similar to periods of physiologic growth, we illustrate an inverse correlation between SPARCL1 expression and high-grade localized prostate cancer as well as metastatic lesions. Consistent with its role in physiologic epithelial invasion during development, we demonstrate that the loss of SPARCL1 expression increases the migratory and invasive properties of prostate epithelial cells through a RHOC-mediated process. We further demonstrate that loss of SPARCL1 expression is not only associated with aggressive disease, but is also independently associated with disease recurrence following treatment, indicating that loss of SPARCL1 expression in the primary tumor may drive metastasis rather than solely being a marker of metastatic lesions. Taken together, these data suggest that by suppressing RHOC mediated migration, SPARCL1 plays a key role in modulating the metastatic potential of cancer and further defines loss of SPARCL1 as an early marker of aggressive prostate cancer.
Recent studies show type I collagen stimulation of the α2β1-integrin promotes prostate cancer cell migration through RHOC activation (12, 50) . We demonstrate here that SPARCL1, a type I collagen-binding protein, attenuates type I collagen-induced RHOC activation and this corresponds to decreased RHOC-mediated migration in the prostate (11) . RHOC has been shown to affect the localization of active Rac1, a distinct member of the RHO family (23) . Consistent with that study and our finding that SPARCL1 negatively regulates RHOC activity, a separate report using a small molecule inhibitor against Rac1 suggests that Sparcl1 inhibits Rac1-dependent migration in fibroblasts (10). Furthermore, although RHOC expression is elevated in multiple cancers, including breast (51), bladder (52) , and nonsmall-cell lung carcinoma (53) , its expression levels do not correlate with prostate cancer aggressiveness. This finding suggests that unlike other tumors, which overexpress RHOC, prostate cancers may regulate RHOC-mediated migration via modulation of SPARCL1 expression. Together, these studies suggest a role for SPARCL1 as a master regulator of RHOC-RAC1 mediated cellular migration and invasion. We demonstrate that SPARCL1 may have clinical utility as a prognostic marker that is independently associated with prostate cancer recurrence. Thus, SPARCL1 expression may identify patients who are in greatest need of additional therapies. In addition, we outline a key biologic role for SPARCL1 in prostate cancer. Thus, it is possible that treatments targeting this pathway could attenuate the metastatic potential of localized cancers and we believe that further understanding of the factors modulating SPARCL1 will have important clinical implications for both prognostic and therapeutic development.
Materials and Methods
Cellular and molecular biology assays including RNA isolation, RT-PCR, in vitro organ culture, antibodies, immunoblotting, IF, 3D prostate invasion, cell culture, cell growth, cell cycle, apoptosis, adhesion, migration, invasion, and activated RHO assays are described in SI Materials and Methods. Animal studies including prostate regeneration, Hi-Myc mice, and TRAMP mice are described in SI Materials and Methods. Cohort studies including the JHU Gleason grade TMAs, the JHU progression analyses, and the Mayo Clinic progression analyses are described in SI Materials and Methods.
